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Inhalant Abuse: Supporting Broad-Based
Research Approaches
The National Institute on Drug Abuse (NIDA) seeks
to broaden the understanding of all aspects of
inhalant abuse (i.e., from epidemiology, to treatment,
to the underlying neurobiological mechanisms).
Prevalence data from both the National Household
Survey (NHS) and Monitoring the Future Survey
(MTF) indicate that inhalant abuse continues to be a
major public health concern among grade school
children, adolescents, and some adults. According to
the 2004 MTF Survey, inhalants stand out in stark
contrast to the progress made in reducing overall
drug use among children and adolescents. Inhalants
pose a particularly signiﬁcant problem since they are
readily accessible, legal, and inexpensive. These fea-
tures mean that they tend to be abused by younger
children, in whom their highly toxic effects can be
even more lethal than in adults. Furthermore, MTF
lifetime prevalence ﬁgures indicate that the percent-
age of students who have tried inhalants remains at
high levels. The NHS indicates that lifetime use of
inhalants is greater than lifetime use of crack cocaine
or heroin. Given the paucity of research on all aspects
of inhalant abuse, this announcement is designed to
encourage broad-based research that has the potential
for informing prevention and treatment interventions
for inhalant abuse, particularly for children and ado-
lescents. Basic epidemiological, behavioral, cognitive
and neurobiological research is needed across chil-
dren and adolescent populations, as are animal mod-
els of preadolescents and adolescents, to determine
the antecedent variables (e.g., impaired decision-mak-
ing processes, impulsivity), consequences (e.g., neu-
rological and physiological disorders, accidents,
dropping out of school, impairments resulting from
prenatal exposure, and cognitive deficits), and the
underlying mechanisms associated with or resulting
from inhalant exposure.
Inhalants are volatile substances that produce
chemical vapors that can be inhaled to induce a psy-
choactive or mind-altering effect. Several subcate-
gories of inhalants have been identified, including:
1) industrial or household products (e.g., paint thin-
ners or solvents, degreasers or cleaning fluids, gaso-
line, and volatile substances in glues); 2) art and
office supply solvents (e.g., correction fluids, glues,
and solvents in magic markers); 3) gases such as
butane and chloroﬂuorocarbons used in household or
commercial products (e.g., butane lighters, whipped
cream dispensers [nitrous oxide], electronic contact
cleaners [dusters] and refrigerant gases); 4) household
aerosol propellants used in items such as hair, cook-
ing, lubricant and fabric protector sprays; 5) medical
anesthetic gases such as ether, chloroform, halothane,
and nitrous oxide; and 6) aliphatic nitrites.
Inhalants are appealing for a variety of reasons:
They are relatively inexpensive, can be purchased
legally, and are readily accessible to most everyone
including those most likely to abuse them—children
and adolescents. Moreover, the “high” from inhalants
onsets and disappears quickly, in comparison to other
drugs of abuse. The practices of “snifﬁng,” “hufﬁng,”
“bagging,” or inhaling to get high are various forms of
inhalation abuse popular among users. Disorders asso-
ciated with inhalant abuse include toluene-induced
hearing loss, cerebellar ataxia, sensory-motor polyneu-
ropathy resulting from nitrous oxide exposure, hexane-
(e.g., methylethylketone) induced peripheral neuropa-
thy, distal-renal acidosis, and cardiac arrhythmias.
Prenatal exposure to inhalants can have adverse
consequences, and research is needed to determine
their short- and long-term effects on infant develop-
ment. Deaths have been attributed to inhalant abuse,
primarily resulting from anoxia and inhalant-abuse–
related accidents. While some of these disorders have
been studied and documented, further study is needed
to understand the underlying mechanisms of these
disorders and the development of interventions to treat
these conditions. Additional research is also needed to
characterize addiction to inhalants and to compare the
abuse of inhalants with abuse of other substances, such
as sedatives and alcohol. Insofar as inhalant abuse is an
international public health concern, epidemiological
research should examine regional and cultural dif-
ferences in the pattern of use and substances abused
among various populations. Treatment and prevention
interventions for inhalant abuse should consider
regional differences and other variables in the develop-
ment and testing of new interventions. Additional
research, therefore, is needed to address all aspects of
inhalant abuse, including the epidemiology, the behav-
ioral, cognitive, and neurobiological antecedents and
consequences of inhalant abuse, as well as the treat-
ment and prevention of inhalant abuse. Specific
research topics that would be appropriate for this ini-
tiative are described below. For further information
about inhalant abuse and this area of research, please
refer to: Inhalant Abuse: A Volatile Research Agenda,
NIDA Monograph 129, 1992; Sharp and Rosenberg,
Inhalants; and “Substance Abuse, a Comprehensive
Textbook,” 3rd ed. pp. 246–264, 1997; Balster, R.,
Neural Basis of Inhalant Abuse. Drug and Alcohol
Dependence, 51: 207–214, 1998.
Research is needed to characterize the nature and
extent of the inhalant abuse for different classes of
abused inhalants in relevant population subgroups.
Studies are needed on the initiation, experimentation,
development, and cessation of inhalant abuse and the
consequences of abuse of different classes of solvents
and gases. Inhalant abuse is widespread and affects
diverse groups in domestic and international popula-
tions. Because of this diversity, studies should consider
sociocultural, socioeconomic, gender, and regional dif-
ferences, as well as factors associated with risk, vulnera-
bility, protection, and resiliency to inhalant abuse and
its consequences. Research is needed to determine how
family support, role models, the extended family, pre-
existing conditions (e.g., HIV/AIDS, mental health
disorders, alcohol and other substance abuse), peer
groups and socioeconomic status affect initiation,
continuation, escalation, and cessation of inhalant use.
Data are needed on the incidence, prevalence, and
trends in abuse of inhalants and on the health conse-
quences (e.g., other drug use, sexually transmitted
infections, including HIV/AIDS) as well as the behav-
ioral and social consequences (e.g., automobile acci-
dents, school dropout) associated with inhalant abuse.
Further research of interest includes, but is not limited
to the following studies: 1) Characterize the nature
and extent of abuse of inhalants among youth and
adolescents in different regions of the nation or world
(e.g., rural, suburban, and urban areas), across cultur-
ally or geographically distinct communities (e.g., com-
munities along the United States–Mexico border),
and among diverse ethnic, socioeconomic, and occu-
pational groups. 2) Characterize trajectories in
inhalant abuse, from grade school to early adolescence
and young adulthood (i.e., initiation, progression,
maintenance, and cessation). 3) Understand the pat-
terns, incidence, and prevalence of inhalant use among
youth at risk, such as school dropouts, gang members,
children of drug users, and homeless youth.
4) Examine diverse social circumstances and interac-
tions of youth, such as peer networks and subcultures,
family dynamics, community context, and communi-
cation technology (e.g., the Internet) and how they
may impact epidemiologic patterns and trends in
inhalant abuse and in the progression of other sub-
stance abuse. 5) Determine reasons for inhalant use,
attitudes and perceived risks of use, knowledge of
potential short- and long-term consequences of use
(e.g., accidents due to inhalant intoxication, health
effects such as CNS toxicity) and reasons for continued
use or cessation of use. 6) Characterize developmental
trends in inhalant abuse, including potential cohort,
secular, and intergenerational trends in the epidemiol-
ogy of use. 7) Identify etiological factors associated
with inhalant use and abuse, including potential pre-
dispositional risk factors (e.g., comorbidity, psychiatric
disorders and other emotional, physical, and
psychosocial stressors) and vulnerabilities associated
with gender, age, ethnicity, and socioeconomic status.
8) Determine progressive behavioral, social, and health
consequences of long-term inhalant abuse, such as
morbidity and mortality, criminal activity, deviancy in
school, familial conﬂicts and abuse, and problems in
employability and job performance. 9) Explore the
relationship between inhalant abuse and use and abuse
of alcohol and other drugs. To what extent and for
whom does availability of alcohol and other drugs lead
to decreased inhalant abuse? Do some inhalant users
continue to use and abuse inhalants despite availability
of other drugs and alcohol, and if so, why? 10) Assess
and compare the incidence and prevalence of abuse
and abuse of particular inhalants in different countries
and regions of the world to understand unique deter-
minants, correlates, and consequences of inhalant
abuse, and to identify opportunities for rapid, targeted
preventive interventions.
Inhalants are widely abused by youngsters due to
their easy accessibility through household products as
well as their low cost. Unfortunately, inhalant abuse
poses definite dangers to the health of young chil-
dren, including cognitive, neurological and physio-
logical disorders, as well as the threat of sudden
death. Inhalant abuse is often associated with behav-
ioral problems such as dropping out of school, delin-
quency, and crime in young people. In fact, inhalants
are considered to be the precursors to later substance
abuse and related psychosocial problems.
Current inhalant prevention strategies focus
on increasing young people’s awareness and informa-
tion regarding the dangers of inhalant abuse. Since
the average age of inhalant initiation is relatively
young, prevention strategies should target not only
young people but their parents and teachers as well.
Therefore, inhalant abuse prevention strategies
should be multicomponent and comprehensive, and
include family-based and school-based components.
Prevention programs should begin in the pri-
mary grades where many young people’s beliefs and
attitudes about drug use are formed. However, care
must be exercised in developing interventions that
avoid unnecessary sensitization of youth to the issue
of inhalant abuse in order to avoid unintended conse-
quences. In fact, media and public information inter-
ventions must be developed according to guidelines,
which on one hand reduce unnecessary sensitization
of youth to the presence of inhalants in certain mate-
rials, and on the other hand educate youth, parents,
teachers, and other adults about the hazards
of inhalants. Inhalant prevention strategies should
include comprehensive approaches that meld care-
fully constructed and developmentally appropriate
media, training, technical assistance, information dis-
semination, and local community action efforts.
The ﬁeld of prevention research should develop
a scientifically sound knowledge base concerning
the efficacy and effectiveness of existing inhalant
abuse prevention strategies and policies, as well as
develop and test innovative intervention strategies.Fellowships, Grants, & Awards
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The development of sex-based prevention interven-
tions are needed that are based on the differential
etiologic factors found in males and females. The fol-
lowing are examples of research topics that address
important gaps in our knowledge of inhalant preven-
tion: 1) Develop and test the efﬁcacy and effectiveness
of inhalant prevention strategies for youth at high-risk
for inhalant abuse in different cultural (e.g., Hispanics,
Native Americans, etc.), geographic (e.g., urban, rural,
etc.), and socioeconomic (e.g., poor, afﬂuent) settings;
2) develop population- or context-speciﬁc universal,
selective, and/or indicated prevention approaches that
can be implemented and administered easily, effi-
ciently, and at low cost; 3) compare and contrast the
efficacy and effectiveness of family-based, school-
based, and multiple-component prevention strategies;
4) develop and test the efficacy and effectiveness of
age-speciﬁc inhalant prevention strategies.
There is a paucity of research on the behavioral
or pharmacotherapeutic approaches to treatment of
inhalant abusers. Inhalant abusers are often excluded
from studies on drug abusers, and there have been no
NIDA-funded studies focusing exclusively on treat-
ing inhalant abusers. Research is needed on behav-
ioral treatments focusing on different populations of
inhalant abusers. Stage I or early behavioral treatment
development research focusing on the development,
reﬁnement, and pilot testing of behavioral interven-
tions are also encouraged under this RFA. For a
description of Stage I research, please see PA-99-107,
A Behavioral Therapies Development Program
at: http://grants.nih.gov/grants/guide/pa-files/
PA-99-107.html.
This includes research that seeks to develop new
therapeutic approaches, or reﬁne or modify existing
behavioral or psychosocial therapeutic approaches
(e.g., forms of cognitive-behavioral therapy, family
therapy, motivational enhancement, drug counseling,
group therapy, motivational incentives, etc.). Stage I
also involves the pilot testing of these therapies. Pilot
testing that seeks to clarify the mechanisms by which
behavioral treatments produce change in inhalant
use, including identiﬁcation of mediators and moder-
ators that influence abuse of inhalants and other
drugs, is encouraged. Such pilot testing may utilize a
variety of designs, including but not limited to single-
case designs, dismantling, additive, and nonparamet-
ric designs, where appropriate. Speciﬁc areas of Stage
I interest include but are not limited to 1) stage I
research that addresses the unique characteristics and
problems of speciﬁc populations of inhalant abusers,
including but not limited to young male and female
adolescents, women, men who have sex with men,
individuals with HIV/AIDS, persons in professions
with extended exposure to inhalants, individuals with
comorbid mental or physical disorders, chemically
dependent pregnant women, adolescents who are
abusing another drug or multiple other drugs, adoles-
cents living in impoverished areas, individuals in the
criminal justice system, or other populations abusing
inhalants. This research may include the develop-
ment of treatment modules that address the unique
characteristics of particular populations of inhalant
abusers and integration of these modules into other
therapeutic approaches; 2) development and pilot
testing of treatments for specific populations of
inhalant abusers based upon recent advancements in
the behavioral, social, or cognitive sciences. Where
appropriate, outcome measures may include, in addi-
tion to measures of substance abuse, other measures
of functioning (e.g., behavioral, social, etc.) and also
measurements of brain functioning (e.g., MRI, PET-
scan, etc.); 3) development and pilot testing of
behavioral treatments tailored to people who have
inhalant-related cognitive impairments; this may
include research that focuses on behavioral therapies
aimed at cognitive rehabilitation, based upon recent
advancements and theories in cognitive neuroscience,
and also may include measurements of changes in
brain function associated with therapeutic interven-
tion; 4) development and pilot testing of behavioral
treatments that have a particular focus on the initial
stage of treatment engagement, including the develop-
ment of “treatment modules” that can be incorporated
into other therapeutic approaches to improve engage-
ment and retention; 5) development and pilot testing
of brief behavioral treatment interventions (e.g., for
use in primary care settings). 6) Other studies should
identify preexisting and co-existing neurobiological,
psychosocial, and environmental factors that signiﬁ-
cantly impact treatment outcomes; 7) determine and
examine the physiology of withdrawal from inhalants,
including the study of potential treatments to amelio-
rate any withdrawal syndrome and determine if differ-
ent classes of inhalants induce different withdrawal
syndromes; 8) develop and improve methods for diag-
nosing, treating, and increasing physician awareness of
inhalant abuse, overdose, and poisoning, including
research aimed at developing and improving analyses
for inhalants that can be used in medical emergency
care or other settings; 9) develop and/or test medica-
tions currently used or under development for other
drug dependencies (e.g., alcohol, sedatives).
Several medical sequelae have been associated
with inhalant abuse, including hearing loss, neurologi-
cal degeneration, metabolic acidosis, loss of cerebellar
function, and cardiac arrhythmia. Additional research
is needed to determine and characterize the neuropsy-
chological, cognitive, behavioral, cellular, and physio-
logical consequences of inhalant abuse using clinical,
animal, and in vitro investigations. Additional research
is needed to develop possible pharmacotherapies to
treat the medical and other related conditions associ-
ated with inhalant abuse including addiction.
Models of inhalant abuse and addiction should
take into account the fact that inhalant abuse occurs
among children and adolescents. The models should
also focus on the pattern of use and how inhalants
are abused. When appropriate, investigators should
measure and model acute and long-term administra-
tion of solvent/gas mixtures, their pharmacodynamic
properties, and the bioavailability of abused solvents
and their metabolites.
Examples of appropriate research topics and
approaches include but are not limited to the follow-
ing: 1) study of the cellular and systemic changes
(e.g., measures of central neurotransmitter systems,
renal metabolic processes, cobalamin systems related
to N2O) involved in single and repeated inhalant
exposure; 2) determination of the mechanisms of the
acute and long-term toxic effects of inhalants on, for
example, central nervous, cardiovascular, renal, pul-
monary, and immune systems. Research could focus
on known inhalant-induced toxicities (e.g., high-
frequency hearing loss, renal acidosis, cerebellar
ataxia); 3) characterization of the acute subjective,
reinforcing and cognitive effects of inhalant abuse and
their underlying neural mechanisms; 4) correlation
between the pharmacokinetic and pharmacodynamic
properties of inhalants and their behavioral, cognitive,
and/or physiologically toxic effects; 5) comparison
of the behavioral, cognitive, and neurobiological
effects of different types of inhalants with each other
or with other abused substances (e.g., alcohol, benzo-
diazepines, dissociative anesthetics or sedatives), focus-
ing on understanding the systems involved and the
basic underlying mechanisms; 6) characterization of
the relative abuse potential of inhalant compounds
using innovative determinations of these substances
and their classiﬁcation; 7) study of tolerance and/or
sensitization to inhalants and determine the underly-
ing neurobiological mechanisms associated with these
phenomena; 8) development of animal models to
study motivational processes, and the environmental
and genetic factors that inﬂuence the acquisition and
maintenance of inhalant self-administration; 9) identi-
fication of the consequences of acute and chronic
inhalant administration on sensory/perceptual, motor,
behavioral, and cognitive processes in known abusers
or with the use of appropriate animal models; study of
cognition in inhalant abusers employing longitudinal
or prospective designs; 10) study of the short- and
long-term developmental consequences of prenatal
exposure to inhalants. Possible ontogenetic conse-
quences of inhalant exposure could be examined at
various stages of development using animal models or
in people exposed perinatally to inhalants; determina-
tion of the nature and characteristics of a possible
Fetal Solvent Syndrome (FSS); 11) study of potential
neurotoxic effects of inhalants in humans (and ani-
mals) using neuroimaging techniques and by using
postmortem tissue analyses; 12) use of neuroimaging
techniques (i.e., PET, fMRI, and other technologies)
to relate neural integrity and changes in metabolic
function with patterns of inhalant use and/or prior
abuse; 13) study of the etiology, diagnosis, progression,
and treatment of HIV/AIDS in inhalant abusers, as
well as complications associated with HIV therapy for
inhalant users (e.g., drug–drug interactions); 14) study
of the short- and long-term consequences of regular
inhalant abuse as a function of age or developmental
period (e.g., adolescence).
This funding opportunity will use the NIH
Research Project Grant (R01), Small Grant (R03),
and the Exploratory/Developmental Grant (R21)
award mechanism(s). As an applicant, you will be
solely responsible for planning, directing, and exe-
cuting the proposed project.
This funding opportunity uses just-in-time con-
cepts. It also uses the modular as well as the non-
modular budget formats (see http://grants.nih.gov/
grants/funding/modular/modular.htm). Specifically,
if you are submitting an application with direct
costs in each year of $250,000 or less, use the modu-
lar budget format described in the PHS 398 applica-
tion instructions, available at http://grants.nih.gov/
grants/funding/phs398/phs398/398.html in an inter-
active format. Otherwise, follow the instructions for
nonmodular research grant applications. For further
assistance contact GrantsInfo, 301-435-0714, (tele-
communications for the hearing impaired: TTY 301-
451-0088), or by e-mail: GrantsInfo@nih.gov.
Applications must be prepared using the most
current PHS 398 research grant application instruc-
tions and forms. Applications must have a D&B
Data Universal Numbering System (DUNS) number
as the universal identiﬁer when applying for Federal
grants or cooperative agreements. The D&B number
can be obtained by calling 866-705-5711 or through
the web site at http://www.dnb.com/us/. The D&B
number should be entered on line 11 of the face
page of the PHS 398 form. For key dates related to
this announcement see http://grants.nih.gov/grants/
funding/submissionschedule/htm.
Contact: David Shurtleff, Division of Basic
Neurosciences and Behavior Research, National
Institute on Drug Abuse/NIH/DHHS, 6001
Executive Boulevard, Room 4282, MSC 9555,
Bethesda, MD 20892-9555 USA, Rockville, MD
20852 USA (for express/courier service), 301-435-
0891, e-mail: dshurtle@nida.nih.gov. Reference: PA
No. PA-05-099